uniQure N.V. - Ordinary Shares (NQ:QURE)

23.46 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗

December 10, 2024

The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.

Via Investor's Business Daily

Why Is uniQure Stock Skyrocketing On Tuesday? ↗

December 10, 2024

uniQure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.

Via Benzinga

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

December 10, 2024

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

November 21, 2024

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

November 05, 2024

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

October 15, 2024

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

September 23, 2024

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

August 15, 2024

From uniQure Inc.

Via GlobeNewswire

CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024

August 02, 2024

Via AB Newswire

Topics Intellectual Property

QURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024 ↗

August 01, 2024

QURE stock results show that uniQure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

August 01, 2024

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

July 23, 2024

From uniQure Inc.

Via GlobeNewswire

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 11, 2024

Via Benzinga

Why Are UniQure Shares Surging Today? ↗

July 10, 2024

UniQure N.V. (NASDAQ: QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's...

Via Benzinga

Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 10, 2024

Via Benzinga

SMART Global Posts Upbeat Results, Joins Aehr Test Systems, MarineMax And Other Big Stocks Moving Higher On Wednesday ↗

July 10, 2024

Via Benzinga

Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

July 10, 2024

Via Benzinga

S&P 500 Edges Higher; Indivior Shares Plummet ↗

July 09, 2024

Via Benzinga

Topics Stocks

Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 09, 2024

Via Benzinga

Crude Oil Down 1%; Soligenix Shares Surge ↗

July 09, 2024

Via Benzinga

Why UniQure Stock Is Soaring ↗

July 09, 2024

UniQure shares are trading higher Tuesday after the company announced updated interim data from its ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington's...

Via Benzinga

MULN Stock Alert: Mullen Announces EV Sale to Spencer Manufacturing ↗

July 09, 2024

Mullen stock is down on Tuesday even as MULN shareholders learn of a new EV order for subsidiary Bollinger Motors from Spencer Manufacturing.

Via InvestorPlace

Why Is uniQure (QURE) Stock Up 51% Today? ↗

July 09, 2024

UniQure stock is up on Tuesday as QURE investors react to positive clinical trial data for its Huntington’s Disease treatment candidate.

Via InvestorPlace

Dow Falls Over 50 Points; US Small Business Optimism Surges In June ↗

July 09, 2024

Via Benzinga

Topics Stocks

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

July 09, 2024

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

July 01, 2024

From uniQure Inc.

Via GlobeNewswire

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

June 03, 2024

From uniQure Inc.

Via GlobeNewswire

QURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

QURE stock results show that uniQure missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 07, 2024

From uniQure Inc.

Via GlobeNewswire

Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy ↗

April 26, 2024

Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.

Via Investor's Business Daily

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.